Close

Anti-B7-H3 (hBRCA84D-2)-Megf10 CAR-MA (CARMA-W2218)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-B7-H3 chimeric antigen receptor (CAR) is constructed for the engineering of macrophage cells to target human B7-H3 and induce target cell phagocytosis. The macrophage cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-B7-H3 antibody (hBRCA84D-2) linked to Megf10 signaling domains. The vector product was designed for the treatment of Glioblastoma, Ovarian cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • B7-H3
  • Cell Type
  • Macrophage
  • Targeting Diseases
  • Glioblastoma, Ovarian cancer
  • Vector Name
  • pCDCAR1
  • Vector length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Size
  • 10 µg
  • Storage
  • Store at -20°C for long term.

CAR Components

  • Promoter
  • EF1a
  • scFv
  • hBRCA84D-2
  • Hinge
  • CD8
  • TM
  • CD8
  • ICD
  • Megf10
  • Marker
  • GFP or N/A
  • Receptor Construction
  • scFv-hinge(CD8)-TM(CD8)-ICD(Megf10)
  • Discription of Signaling Cassetes
  • Megf10:
    Megf10 is used as the CAR intracellular signaling domain. As a phagocytosis receptor, Megf10 has cytosolic Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) that are phosphorylated by Src family kinases. Based on this mechanism, Megf10 signaling can induce macrophage phagocytosis which has been demonstrated in the published article.
    It is a membrane receptor involved in phagocytosis by macrophages and astrocytes of apoptotic cells. It's a receptor for C1q, an eat-me signal, that binds phosphatidylserine expressed on the surface of apoptotic cells

Target

  • Target
  • B7-H3
  • Target Species
  • Human
  • Clone
  • hBRCA84D-2
  • Host
  • Humanized
  • Gene Name
  • CD276 molecule
  • Introduction
  • The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. Studies show that while the transcript of this gene is ubiquitously expressed in normal tissues and solid tumors, the protein is preferentially expressed only in tumor tissues. Additionally, it was observed that the 3' UTR of this transcript contains a target site for miR29 microRNA, and there is an inverse correlation between the expression of this protein and miR29 levels, suggesting regulation of expression of this gene product by miR29. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
  • Alternative Names
  • CD276; CD276 molecule; B7H3; B7-H3; B7RP-2; 4Ig-B7-H3

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-B7-H3 (hBRCA84D-2) ICD(Megf10) CAR-MA Plasmid, pCDCAR1 (CARMA-W2218). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.